The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10

Vaccine

Volumn 26, Issue 42, 2008, Pages 5352-5357

  Lu, Xiao ling ^a   Jiang, Xiao bing ^b   Liu, Ru en ^c   Zhang, Sheng min ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Anti angiogenic; Cytolytic T lymphocyte; Immunotherapy; IP 10

Indexed keywords

CYCLINE; DNA VACCINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; ENDOTHELIUM CELL; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; MELANOMA; MOUSE; NICK END LABELING; NONHUMAN; PLASMID; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SPLEEN CELL; SURVIVAL TIME; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CANCER VACCINES; CHEMOKINE CXCL10; COMBINED MODALITY THERAPY; FEMALE; GENE THERAPY; GENETIC VECTORS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PLASMIDS; SALMONELLA TYPHIMURIUM; VACCINES, ATTENUATED; VACCINES, DNA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 51349109961     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.012     Document Type: Article

References (36)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 21 (1971) 1182-1186
2. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2 10 (2002) 727-739
3. Eskens F.A. Angiogenesis inhibitors in clinical development; where are we now and where are we going?. Br J Cancer 90 1 (2004) 1-7
4. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., and Holash J. Vascular-specific growth factors and blood vessel formation. Nature 407 6801 (2000) 242-248
5. Shweiki D., Itin A., Soffer D., and Keshet E. Vascular endothelial growth-factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 6398 (1992) 843-845
6. Wei Y.Q., Wang Q.R., Zhao X., Yang L., Tian L., Lu Y., et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 6 10 (2000) 1160-1166
7. Li Y., Wang M.N., Li H., King K.D., Bassi R., Sun H., et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 195 12 (2002) 1575-1584
8. Niethammer A.G., Xiang R., Becker J.C., Wodrich H., Pertl U., Karsten G., et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8 12 (2002) 1369-1375
9. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 6 (2002) 15-18
10. Tonini T., Rossi F., and Claudio P.P. Molecular basis of angiogenesis and cancer. Oncogene 22 42 (2003) 6549-6556
11. Luster A.D., and Leder P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent anti-tumor response in vivo. J Exp Med 178 3 (1993) 1057-1065
12. Sgadari C., Angiolillo A.L., Cherney B.W., Pike S.E., Farber J.M., Koniaris L.G., et al. Interferoninducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 93 24 (1996) 13791-13796
13. Arenberg D.A., Kunkel S.L., Polverini P.J., Morris S.B., Burdick M.D., Glass M.C., et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184 3 (1996) 981-992
14. Narvaiza I., Mazzolini G., Barajas M., Duarte M., Zaratiegui M., Qian C., et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol 164 6 (2000) 3112-3122
15. Taub D.D., Longo D.L., and Murphy W.J. Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues and human peripheral blood lymphocytes-SCID mice. Blood 87 4 (1996) 1423-1431
16. Taub D.D., Sayers T.J., Carter C.R., and Ortaldo J.R. Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol 155 8 (1995) 3877-3888
17. 2+ mobilization, and enzyme release. J Immunol 156 1 (1996) 322-327
18. Luster A.D., Greenberg S.M., and Leder P. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 182 (1995) 219-231
19. Angiolillo A.L., Sgadari C., Taub D.D., Liao F., Farber J.M., Maheshwari S., et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182 1 (1995) 155-162
20. Matthews W., Jordan C.T., Gavin M., Jenkins N.A., Copeland N.G., and Lemischka I.R. Areceptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 88 20 (1991) 9026-9030
21. Garlanda C., Parravicini C., Sironi M., Rossi M.D., de Calmanovici R.W., Carozzi F., et al. Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. Proc Natl Acad Sci USA 91 15 (1994) 7291-7295
22. Terando A.M., Faries M.B., and Morton D.L. Vaccine therapy for melanoma: current status and future directions. Vaccine 25 S2 (2007) B4-B16
23. Enk A.H., Becker J.C., and Schuler G. Immunotherapy of malignant melanoma-basic principles and novel therapeutic approaches. J Dtsch Dermatol Ges 4 8 (2006) 635-645
24. Toomey D., Conroy H., Jarnicki A.G., Higgins S.C., Sutton C., and Mills K.H.G. Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma. Vaccine 26 27-28 (2008) 3540-3549
25. Feng K.K., Zhao H.Y., Qiu H., Liu J.X., and Chen J. Combined therapy with Flk-1-1based DNA vaccine and IL12 results in enhanced antiangiogenic and antitumors effects. Cancer Lett 221 1 (2005) 41-47
26. Neville L.F., Mathiak G., and Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 8 3 (1997) 207-219
27. Luster A.D., and Ravetch J.V. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 166 4 (1987) 1084-1097
28. Krathwohl M.D., and Anderson J.L. Chemokine CXCL10 (IP-10) is sufficient to trigger an immune response to injected antigens in a mouse model. Vaccine 24 15 (2006) 2987-2993
29. Vockerodt M., Pinkert D., Smola-Hess S., Michels A., Ransohoff R.M., Tesch H., et al. The Epstein-Barr virus oncoprotein latent membrane protein 1 induces expression of the chemokine IP-10: importance of mRNA half-life regulation. Int J Cancer 114 4 (2005) 598-605
30. Huang H., Liu Y., and Xiang J. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 trans-gene expression in treatment of established tumors. Cell Immunol 217 1-2 (2002) 12-22
31. Dufour J.H., Dziejman M., Liu M.T., Leung J.H., Lane T.E., and Luster A.D. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168 7 (2002) 3195-3204
32. Xanthou G., Williams T.J., and Pease J.E. Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation. Eur J Immunol 33 10 (2003) 2927-2936
33. Keyser J., Schultz J., Ladell K., Elzaouk L., Heinzerling L., and Pavlovic J. IP-10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic efficiency. Exp Dermatol 13 6 (2004) 380-390
34. Arenberg D.A., Kunkel S.L., Polverini P.J., Morris S.B., Burdick M.D., Glass M.C., et al. Interferongamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184 3 (1996) 981-992
35. Wildbaum G., Netzer N., and Karin N. T cell polarization and suppresses experimental autoimmune encephalomyelitis. J Immunol 168 11 (2002) 5885-5892
36. Tsunoda I., Lane T.E., Blackett J., and Fujinami R.S. Distinct roles for IP-10/C XC L10 in three animal models, Theiler's virus infection, EA E, and MHV infection, for multiple sclerosis: implication of differing roles for IP-10. Multiple Sclerosis 10 1 (2004) 26-34